Hepatocellular Carcinoma Situation in Indonesia: A Systematic Review of Clinical Staging and Histological Characteristics at the Time of Diagnosis
Main Article Content
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. However, systematic data on HCC characteristics in Indonesia are limited.
Objective: To summarize the body of literature on the characteristics of HCC in Indonesia.
Methods: A comprehensive search was conducted in MEDLINE, ScienceDirect, Scopus, Web of Science, and Google Scholar databases without date restrictions. Clinical studies investigating the characteristics of HCC exclusively in Indonesia were eligible for inclusion. Risk-of-bias assessments were conducted, and results were presented descriptively.
Results: Ten studies comprising 1,389 HCC patients were included. The Barcelona Clinic Liver Cancer (BCLC) staging system, reported in 5 studies, revealed a predominance of intermediate to advanced stages (B and C) at diagnosis. Child-Pugh scores, available for 7 studies, indicated variability in liver function, with Child-Pugh A ranging from 12.0% to 85.7%. Hepatitis B virus (HBV) infection was the primary etiological factor, with prevalence ranging from 53.8% to 84.0%. Hepatitis C virus (HCV) infection was less common (1.0% to 25.21%). Non-viral etiologies represented a substantial proportion, reaching up to 37.4% of cases. The mean age at diagnosis ranged from 52.43 to 63.1 years.
Conclusion: This review highlights the late-stage presentation of HCC in Indonesia, the predominance of HBV as an etiological factor, and a significant burden of non-viral HCC. The findings underscore the need for improved early detection strategies, strengthened HBV prevention efforts, and increased attention to metabolic risk factors. Regional variations in HCC characteristics suggest the need for tailored approaches to HCC management across different parts of Indonesia.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Akarca, U. S., Unsal, B., Sezgin, O., Yalcin, K., Akdogan, M., Gonen, C., Gunduz, F., Ozenirler, S., Sonsuz, A., Dincer, D., Tekin, S. B., Yucel, I., Akbulut, H., Alkım, C., Ozyilkan, O., Baygul, A., Cevik, Z. M., Idilman, R., & Study Group, O. B. O. K. R. (2021). Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study. The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology, 32(12), 1019–1028. https://doi.org/10.5152/tjg.2021.201171
II. Aprilicia, G., Bantas, K., Syarif, S., & Kalista, K. (2021). Comparative Evaluation of Alpha-Fetoprotein Serum inHepatocellular Carcinoma Patients with Non-Viral Etiology. Jurnal Penyakit Dalam Indonesia, 8(1). https://doi.org/10.7454/jpdi.v8i1.566
III. Asafo-Agyei, K. O., & Samant, H. (2024). Hepatocellular Carcinoma. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK559177/
IV. Batheja, S., Sahoo, R. K., Tarannum, S., Vaiphei, K. K., Jha, S., Alexander, A., Goyal, A. K., & Gupta, U. (2023). Hepatocellular carcinoma: Preclinical and clinical applications of nanotechnology with the potential role of carbohydrate receptors. Biochimica et Biophysica Acta (BBA) - General Subjects, 1867(10), 130443. https://doi.org/10.1016/j.bbagen.2023.130443
V. Effendi K, S. M., Rahadiani N, Stephanie M, Kurebayashi Y, Tsujikawa H, Jasirwan COM, Syaiful RA. (2024). Comparative Immunohistochemical Analysis of Clinicopathological Subgroups in Hepatocellular Carcinomas from Japan and Indonesia. https://doi.org/10.1016/j.jceh.2024.101451
VI. GLOBOCAN. (2024). Indonesia Factsheet, Cancer Today 2022. International Agency for Research on Cancer.
VII. Hasan, I., Loho, I., Lesmana, C., & Gani, R. (2020). Liver Function and Treatment Modalities are Predictors of Survival in Patients with Hepatocellular Carcinoma. Jurnal Penyakit Dalam Indonesia, 7(3). https://doi.org/10.7454/jpdi.v7i3.460
VIII. Herningtyas, E. H., & Ng, T. S. (2019). Prevalence and distribution of metabolic syndrome and its components among provinces and ethnic groups in Indonesia. BMC Public Health, 19(1), 377. https://doi.org/10.1186/s12889-019-6711-7
IX. Jasirwan, C. O. M., Hasan, I., Sulaiman, A. S., Lesmana, C. R. A., Kurniawan, J., Kalista, K. F., Nababan, S. H., & Gani, R. A. (2020). Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. CURRENT PROBLEMS IN CANCER, 44(1). https://doi.org/10.1016/j.currproblcancer.2019.05.003
X. Kim, D. Y. (2024). Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. Journal of Liver Cancer, 24(1), 62–70. https://doi.org/10.17998/jlc.2024.03.13
XI. Kulik, L., & El-Serag, H. B. (2019). Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 156(2), 477-491.e1. https://doi.org/10.1053/j.gastro.2018.08.065
XII. Muljono, D. H. (2017). Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian Journal of Hepato-Gastroenterology, 7(1), 55. https://doi.org/10.5005/jp-journals-l0018-1212
XIII. Nandennavar, M. I., Karpurmath, S. V., Mandakalatur, G., & Prasad, A. E. (2017). Clinical profile of hepatocellular carcinoma and experience with sorafenib from a tertiary cancer centre in Southern India. International Journal of Research in Medical Sciences, 5(2), 379. https://doi.org/10.18203/2320-6012.ijrms20170039
XIV. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, n71. https://doi.org/10.1136/bmj.n71
XV. Park, J.-W., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P.-J., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., & Sherman, M. (2015). Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver International, 35(9), 2155–2166. https://doi.org/10.1111/liv.12818
XVI. Puri, D. A., Murti, S., & Riastiti, Y. (2021). Insidensi dan Karakteristik Karsinoma Hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda: Incidence and Characteristics of Hepatocellular Carcinomas in RSUD Abdul Wahab Sjahranie Samarinda. Jurnal Sains Dan Kesehatan, 3(2), Article 2. https://doi.org/10.25026/jsk.v3i2.275
XVII. Ratnasari, N., Nurdjanah, S., Sadewa, A. H., & Hakimi, M. (2016). The role of vascular endothelial growth factor −634 G/C and its soluble receptor on chronic liver disease and hepatocellular carcinoma. Arab Journal of Gastroenterology, 17(2), 61–66. https://doi.org/10.1016/j.ajg.2016.06.005
XVIII. Siregar, G. A., & Buulolo, B. A. (2018). Factors associated with tumor size of hepatocellular carcinoma. 1ST INT CONF ON TROP MED & INFECT DIS FAC OF MED UNIV SUMATERA UTARA IN CONJUNCTION WITH THE 23RD NATL CONGRESS OF THE INDONESIAN SOC OF TROP & INFECT DIS CONSULTANT AND THE 18TH ANNUAL MEETING OF INTERNAL MED DEPT FAC OF MED UNIV SUMATERA UTARA, 125. https://doi.org/10.1088/1755-1315/125/1/012137
XIX. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
XX. Suriapranata IM, T. S., Sudania WM, Tjong WY, Suciptan AA, Gani RA, Hasan I, Sanityoso A, Budihusodo U, Miskad UA, Akil F, Lelosutan SA, Martamala R, Yusuf I, Lesmana LA, Sulaiman A. (2010). Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. https://doi.org/10.1016/j.cca.2009.11.030
XXI. Syaiful, R. A., Mazni, Y., Siagian, N. K. P., Putranto, A. S., Jeo, W. S., Rahadiani, N., Ibrahim, F., Sihardo, L., Marbun, V. M. G., Lalisang, A. N. L., & Lalisang, T. J. M. (2024). Surgical resection for hepatocellular carcinoma: A single-centre’s one decade of experience. ANNALS OF MEDICINE AND SURGERY, 86(3), 1289–1296. https://doi.org/10.1097/MS9.0000000000001746
XXII. Wang, B., Ma, W., Sulaiman, A., Noer, S., Sumoharjo, S., Sumarsidi, D., Tandon, B., Nakao, K., Mishiro, S., Miyakawa, Y., Akahane, V., & Suzuki, H. (2002). Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: Survey of 414 patients from four countries. JOURNAL OF MEDICAL VIROLOGY, 67(3), 394–400. https://doi.org/10.1002/jmv.10087
XXIII. Yang, J. D., Altekruse, S. F., Nguyen, M. H., Gores, G. J., & Roberts, L. R. (2017). Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer, 123(1), 81–89. https://doi.org/10.1002/cncr.30246
XXIV. Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nature Reviews. Gastroenterology & Hepatology, 16(10), 589–604. https://doi.org/10.1038/s41575-019-0186-y